Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …

Advances in HER2-targeted therapies have improved the survival of patients with HER2-
positive breast cancer. The standard-of-care treatment for localized disease has been …

Simple Summary HER2-positive breast cancer (BC), which accounts for~ 20% of BC, is one
of the more aggressive and has the worst overall survival rate among them. These patients …

Breast cancer is the most frequently diagnosed cancer and the principal cause of mortality
by malignancy in women and represents a main problem for public health worldwide. Tumor …

HER2-positive breast cancer (HER2+ BC) represents 15–20% of all BCs. In the last two
decades, the introduction of monoclonal antibodies (MoAbs), tyrosine kinase inhibitors …

Simple Summary Trastuzumab is a humanized antibody that has significantly improved the
management and treatment outcomes of patients with cancers that overexpress HER2 …

Antibody‐drug conjugates (ADCs) are a rapidly developing therapeutic approach in cancer
treatment that has shown remarkable activity in breast cancer. Currently, there are two ADCs …

Human epidermal growth factor receptor (HER) 2 (HER2) is overexpressed in 20–30% of
breast cancers. HER2 is a preferred target for treating HER2-positive breast cancer …

Simple Summary Breast cancer is the most common cancer in women in the United States.
Around 15% of all breast cancers overexpress the HER2 protein. These HER2-positive …

Purpose: Camelid single-domain antibody-fragments (sdAb) have beneficial
pharmacokinetic properties, and those targeted to HER2 can be used for imaging of HER2 …